JANX vs NOC · rev $10.3M vs P/E 17, rev $20.76B
Janux Therapeutics Inc (JANX) versus Northrop Grumman Corporation (NOC) — a side-by-side from cached financials, not a winner call.
Janux Therapeutics Inc (JANX) is a biotechnology company listed on US.
Northrop Grumman Corporation (NOC) is a aerospace & defense company listed on NYSE.
Latest reported JANX revenue for 2026-06-30 was $10.3M. Net income was -$22.0M. JANX currently screens at market cap $1.49B.
Latest reported NOC revenue for 2026-06-30 was $20.76B. Net income was $1.97B. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
JANX currently screens at market cap $1.49B. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
Not investment advice. Open the JANX and NOC stock pages for the full models.
Not investment advice.